Browsing Clinical Studies by author "Kaye, Stanley Bernard"
Now showing items 1-2 of 2
-
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; et al. (2016-04)Background The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by ... -
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ...